KALV — Kalvista Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $488.12m
- $412.53m
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 16.1 | 12.7 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 45.9 | 53.2 | 57.9 | 96.6 | 111 |
Operating Profit | -29.8 | -40.5 | -57.9 | -96.6 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.7 | -29.2 | -46.2 | -82.3 | -92.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.8 | -29.1 | -46.2 | -82.3 | -92.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.8 | -29.1 | -46.2 | -82.3 | -92.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.8 | -29.1 | -46.2 | -82.3 | -92.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.38 | -1.64 | -2.42 | -3.36 | -3.33 |